Evidence map›Paper›PMID 31819405›Full record

Trial reportInternational journal of chronic obstructive pulmonary disease2019

Effect of Erdosteine on COPD Exacerbations in COPD Patients with Moderate Airflow Limitation.

Peter Ma Calverley, Clive Page, Roberto W Dal Negro, Giovanni Fontana, Mario Cazzola, Arrigo F Cicero, Edoardo Pozzi, Jadwiga A Wedzicha

Open access · goldAbstract readClinical Trial, Phase IIIMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in International journal of chronic obstructive pulmonary disease, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.0field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 33 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Oxidative Stress in Chronic Obstructive Pulmonary Disease.Antioxidants (Basel, Switzerland) · 2022
    Review
  11. Article
  12. Review
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 2 countries.

Peter Ma CalverleyDepartment of Medicine, Clinical Sciences Centre, University Hospital Aintree, Liverpool, UK.
Clive PageFaculty of Life Sciences and Medicine, King's College, London, UK.ORCID 0000-0002-9358-3799
Roberto W Dal NegroLung Unit, National Centre for Respiratory Pharmacoeconomics and Pharmacoepidemiology, Verona, Italy.
Giovanni FontanaPulmonology Department, Cough Centre, Careggi University Hospital, Firenze, Italy.ORCID 0000-0003-3261-4544
Mario CazzolaDepartment of Systems Medicine, Chair of Respiratory Medicine, University of Rome 'Tor Vergata', Rome, Italy.ORCID 0000-0003-4895-9707
Arrigo F CiceroMedical and Surgical Department, University of Bologna, Bologna, Italy.
Edoardo PozziMedical Affairs Department, Edmond Pharma, Paderno, Italy.ORCID 0000-0003-2329-5895
Jadwiga A WedzichaRespiratory Division, National Heart And Lung Institute, Imperial College London, London, UK.
Azienda Ospedaliero-Universitaria Careggi · ITImperial College London · GBKing's College London · GBUniversity of Bologna · ITUniversity of Liverpool · GBUniversity of Rome Tor Vergata · ITUniversity of Verona · IT

Funding

Medical Research Council G0800570Medical Research Council G1001365Medical Research Council G1001372
6 · The paper itself

Abstract

Background: The RESTORE study, a multi-national randomized, placebo-controlled study, showed that erdosteine - a muco-active antioxidant that modulates bacterial adhesiveness - reduced the rate and duration of exacerbations in moderate and severe COPD with a history of exacerbations. How much benefit patients with less severe disease experience when taking this drug remains unclear. Methods: This post hoc analysis of the 254 RESTORE participants with spirometrically-defined moderate COPD (post-bronchodilator forced expiratory volume in 1 second [FEV Results: Patients with moderate COPD received erdosteine 300 mg twice daily (n=126) or placebo (n=128) added to usual COPD therapy for 12 months. During this time, there were 53 exacerbations in the erdosteine group and 74 in the placebo group, with 42.1% and 57.8% of patients, respectively, experiencing an exacerbation. There was a 47% reduction in the mean exacerbation rate with erdosteine compared to placebo (0.27 vs 0.51 exacerbations per-patient per-year, respectively, Conclusion: These results indicate that adding erdosteine to usual COPD maintenance therapy reduces the number of mild, and duration of all, exacerbations in patients with moderate COPD and a history of exacerbations.

Indexed as

AdultAgedAged, 80 and overAntioxidantsDisease ProgressionDouble-Blind MethodEuropeExpectorantsFemaleForced Expiratory VolumeHumansLungMaleMiddle AgedPulmonary Disease, Chronic ObstructiveRecovery of FunctionAntioxidantserdosteineExpectorantsThioglycolatesThiophenesanti-inflammatoryantioxidantchronic obstructive pulmonary diseaseCOPD exacerbationserdosteine

Identifiers

PMID31819405
PMCPMC6896911
OpenAlexW2990840608

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.